IRIS UniCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.011
NA - Nord America 3.924
AS - Asia 2.324
SA - Sud America 449
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
AN - Antartide 1
Totale 11.785
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.812
DE - Germania 1.250
IT - Italia 1.230
SG - Singapore 1.084
CN - Cina 685
SE - Svezia 595
FR - Francia 478
PL - Polonia 451
BR - Brasile 366
UA - Ucraina 330
GB - Regno Unito 191
IE - Irlanda 140
IN - India 127
FI - Finlandia 90
ID - Indonesia 85
VN - Vietnam 82
NL - Olanda 73
RU - Federazione Russa 67
TR - Turchia 61
CA - Canada 58
AR - Argentina 41
BD - Bangladesh 32
JP - Giappone 32
HK - Hong Kong 29
MX - Messico 28
BE - Belgio 26
ZA - Sudafrica 22
IR - Iran 19
ES - Italia 17
IQ - Iraq 16
AT - Austria 11
EC - Ecuador 10
LT - Lituania 10
VE - Venezuela 10
EG - Egitto 8
JM - Giamaica 8
MA - Marocco 8
PK - Pakistan 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
CH - Svizzera 7
CZ - Repubblica Ceca 7
KE - Kenya 7
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
PE - Perù 6
JO - Giordania 5
PY - Paraguay 5
UZ - Uzbekistan 5
CL - Cile 4
DK - Danimarca 4
DZ - Algeria 4
HN - Honduras 4
PA - Panama 4
PH - Filippine 4
PT - Portogallo 4
TN - Tunisia 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GR - Grecia 3
KR - Corea 3
LB - Libano 3
LU - Lussemburgo 3
NI - Nicaragua 3
RO - Romania 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
HR - Croazia 2
HU - Ungheria 2
IM - Isola di Man 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MC - Monaco 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CD - Congo 1
CO - Colombia 1
CY - Cipro 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MM - Myanmar 1
NC - Nuova Caledonia 1
Totale 11.774
Salva come PNG Salva come JPEG
Città #
Chandler 653
Singapore 460
Kraków 426
Ashburn 396
Rome 289
Jacksonville 248
New York 176
Milan 173
San Mateo 156
Dublin 138
Nanjing 135
Ann Arbor 122
Beijing 98
Los Angeles 95
Dearborn 86
Nürnberg 83
Jakarta 82
Houston 81
Wilmington 76
Lawrence 71
Cattolica 66
Woodbridge 62
Boston 59
Nanchang 57
Lancaster 53
Dallas 51
Redmond 50
Izmir 46
Redwood City 42
Seattle 37
The Dalles 36
Hefei 34
Shenyang 34
Verona 32
Ho Chi Minh City 31
Moscow 31
Boardman 30
Buffalo 28
Hong Kong 28
Munich 28
Frankfurt am Main 27
Brussels 26
Bremen 25
Kunming 25
Naples 25
Tokyo 25
São Paulo 24
Changsha 23
Fairfield 23
Mountain View 23
Hebei 22
Norwalk 21
Falls Church 20
Hanoi 20
Santa Clara 20
Warsaw 20
Düsseldorf 18
Ottawa 18
Shanghai 18
Turin 18
Leawood 17
Montreal 17
University Park 17
Augusta 15
Marseille 15
Bologna 14
Brooklyn 14
Tianjin 14
Toronto 14
Guangzhou 13
Hangzhou 13
Jinan 13
London 13
Orem 13
Rio de Janeiro 13
Chicago 12
Fremont 12
Johannesburg 12
Poplar 12
Pune 12
Bari 11
Lauterbourg 11
Roubaix 11
Washington 11
Manchester 10
Phoenix 10
Atlanta 9
Brasília 9
Chennai 9
Helsinki 9
Simi Valley 9
Stockholm 9
Amsterdam 8
Bexley 8
Kent 8
Portsmouth 8
Princeton 8
Zhengzhou 8
Baku 7
Belo Horizonte 7
Totale 5.775
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 1.167
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 255
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 238
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 214
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 211
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 206
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 200
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 192
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 190
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 183
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 181
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 178
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 171
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 164
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 162
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 162
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 160
Variability of raltegravir plasma levels in the clinical setting 160
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 159
Initial antifungal strategy does not correlate with mortality in patients with candidemia 159
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 157
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 156
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 151
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 146
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 145
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 144
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 144
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 143
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 143
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 141
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 140
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 140
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 140
Cognitive reserve and neuropsychological functioning in older HIV-infected people 140
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 138
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 137
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 136
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 135
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 134
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 134
Effect of aging and human immunodeficiency virus infection on cognitive abilities 133
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 133
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 132
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 132
Immune response to influenza A(H1N1)v in HIV-infected patients 130
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 129
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 128
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 128
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 128
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 127
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 127
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 127
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 125
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 123
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 122
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 121
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 116
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 115
Lipid-lowering effect of tenofovir in HIV-infected patients 115
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 114
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 113
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 111
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 111
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 108
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 108
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 107
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 104
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 102
Immune response to influenza A(H1N1)v in HIV-infected patients 100
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 99
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 86
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 80
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 80
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 77
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 76
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 74
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 66
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 63
Totale 11.862
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021403 0 0 0 0 0 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/20251.913 55 55 120 103 222 89 99 160 332 154 294 230
2025/20262.195 570 97 200 442 721 165 0 0 0 0 0 0
Totale 11.862